A biomarker has been identified that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
A biomarker has been identified that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.